REG - Barclays PLC Nektar Therapeutics - Form 8.3 - NEKTAR THERAPEUTICS
11/10/2022 14:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221011:nRSK5266Ca&default-theme=true
RNS Number : 5266C Barclays PLC 11 October 2022
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Barclays PLC.
(b) Owner or controller of interest and short
positions disclosed, if different from 1(a):
(c) Name of offeror/offeree in relation to whose NEKTAR THERAPEUTICS
relevant securities this form relates:
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken: 10 Oct 2022
(f) In addition to the company in 1(c) above, is the discloser making NO
disclosures in respect of any other party to the offer?
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of the offeror or
offeree
to which the disclosure relates following the dealing(if any)
Class of relevant security: USD 0.0001 common
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
and/or controlled: 144,447 0.08% 234,331 0.13%
(2) Cash-settled derivatives:
and/or controlled: 7,807,554 4.17% 0 0.00%
(3) Stock-settled derivatives (including options)
and agreements to purchase/sell: 4,800 0.00% 0 0.00%
TOTAL: 7,956,801 4.25% 234,331 0.13%
(b) Rights to subscribe for new securities (including directors and other
executive
options)
Class of relevant security in relation to
which subscription right exists
Details, including nature of the rights
concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security securities
USD 0.0001 common Purchase 1 3.5800 USD
USD 0.0001 common Purchase 10 3.5520 USD
USD 0.0001 common Purchase 14 3.5371 USD
USD 0.0001 common Purchase 24 3.5000 USD
USD 0.0001 common Purchase 64 3.5890 USD
USD 0.0001 common Purchase 96 3.5624 USD
USD 0.0001 common Purchase 200 3.5750 USD
USD 0.0001 common Purchase 200 3.5450 USD
USD 0.0001 common Purchase 200 3.5300 USD
USD 0.0001 common Purchase 207 3.5100 USD
USD 0.0001 common Purchase 224 3.5505 USD
USD 0.0001 common Purchase 251 3.5440 USD
USD 0.0001 common Purchase 386 3.5310 USD
USD 0.0001 common Purchase 436 3.5298 USD
USD 0.0001 common Purchase 437 3.5600 USD
USD 0.0001 common Purchase 500 3.5540 USD
USD 0.0001 common Purchase 788 3.5442 USD
USD 0.0001 common Purchase 1,000 3.5370 USD
USD 0.0001 common Purchase 1,100 3.5454 USD
USD 0.0001 common Purchase 1,400 3.5400 USD
USD 0.0001 common Purchase 2,500 3.5133 USD
USD 0.0001 common Purchase 3,708 3.5462 USD
USD 0.0001 common Purchase 6,496 3.5513 USD
USD 0.0001 common Purchase 8,075 3.5407 USD
USD 0.0001 common Purchase 10,300 3.5285 USD
USD 0.0001 common Purchase 11,907 3.5395 USD
USD 0.0001 common Purchase 12,802 3.5500 USD
USD 0.0001 common Purchase 16,354 3.5468 USD
USD 0.0001 common Purchase 34,683 3.5348 USD
USD 0.0001 common Sale 100 3.4800 USD
USD 0.0001 common Sale 204 3.5715 USD
USD 0.0001 common Sale 206 3.5100 USD
USD 0.0001 common Sale 400 3.5275 USD
USD 0.0001 common Sale 920 3.5308 USD
USD 0.0001 common Sale 986 3.5687 USD
USD 0.0001 common Sale 1,100 3.5390 USD
USD 0.0001 common Sale 2,404 3.5422 USD
USD 0.0001 common Sale 2,995 3.5491 USD
USD 0.0001 common Sale 4,146 3.5476 USD
USD 0.0001 common Sale 6,108 3.5415 USD
USD 0.0001 common Sale 6,706 3.5352 USD
USD 0.0001 common Sale 6,800 3.5164 USD
USD 0.0001 common Sale 12,802 3.5500 USD
USD 0.0001 common Sale 27,411 3.5461 USD
USD 0.0001 common Sale 41,075 3.5353 USD
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price per
relevant description reference unit
security securities
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class Product Writing, Number Exercise Type Expiry Option
of description purchasing, of price date money
relevant selling, securities per unit paid/
security varying etc to which received
option per unit
relates
(ii) Exercising
Class of relevant Product description Exercising/ exercised against Number of Exercise price per
security securities unit
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of Dealings Details Price per unit (if
security applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealings arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding,
formal or informal, relating to relevant securities which may be an inducement
to deal
or refrain from dealing entered into by the exempt principal trader making the
disclosure and any party
to the offer or any person acting in concert with a party to the offer:
NONE
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between
the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights of future acquisition or disposal of any relevant
securities to which
any derivative is referenced:
NONE
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 11 Oct 2022
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213
DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO
PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Identity of the person whose positions/dealings Barclays PLC.
are being disclosed:
Name of offeror/offeree in relation to whose NEKTAR THERAPEUTICS
relevant securities this from relates:
2. OPTIONS AND DERIVATIVES
Class of relevant security Product description Writing, purchasing, selling, varying etc Number of securities to which option relates Exercise price per unit Type Expiry date
USD 0.0001 common Call Options Purchased 500 22.0000 American 16 Dec 2022
USD 0.0001 common Call Options Purchased 4,300 20.0000 American 16 Dec 2022
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position
can be fully understood:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RETBKDBKNBDDFKDRecent news on Barclays
See all newsREG - Barclays PLC Just Group plc - Form 8.3 JUST GROUP PLC
AnnouncementREG - Barclays PLC British Land Co PLC - Form 8.3 BRITISH LAND COMPANY PLC, THE
AnnouncementREG - Barclays PLC Spire Healthcare Grp - Form 8.3 SPIRE HEALTHCARE GROUP PLC
AnnouncementREG - Barclays PLC Life Science REIT - Form 8.3 LIFE SCIENCE REIT PLC
AnnouncementREG - Barclays PLC Intnl Personal Fin - Form 8.3 INTERNATIONAL PERSONAL FINANCE PLC
Announcement